ACLX

Arcellx, Inc.

52.20 USD
+1.75 (+3.47%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arcellx, Inc. stock is up 4.36% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 2 May’s closed higher than April. In the last 2 Unusual Options Trades, there were 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
01 Apr 13:39 19 Apr, 2024 70.00 PUT 106 514
16 Apr 19:28 19 Apr, 2024 60.00 PUT 2000 2138

About Arcellx, Inc.

Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.

  • Stifel
    Wed May 15, 06:46
    buy
    confirm
  • Evercore Partners
    Tue May 14, 05:18
    buy
    initial
  • HC Wainwright & Co.
    Mon May 13, 13:39
    buy
    confirm
  • Needham
    Fri May 10, 15:28
    buy
    confirm
  • Needham
    Tue May 7, 05:28
    buy
    confirm